当前位置: X-MOL 学术Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy
Cancer ( IF 6.1 ) Pub Date : 2021-06-28 , DOI: 10.1002/cncr.33675
Sangeetha Venugopal 1 , Mahran Shoukier 1 , Marina Konopleva 1 , Courtney D Dinardo 1 , Farhad Ravandi 1 , Nicholas J Short 1 , Michael Andreeff 1 , Gautam Borthakur 1 , Naval Daver 1 , Naveen Pemmaraju 1 , Koji Sasaki 1 , Guillermo Montalban-Bravo 1 , Kayleigh R Marx 2 , Sherry Pierce 1 , Uday R Popat 3 , Elizabeth J Shpall 3 , Rashmi Kanagal-Shamanna 4 , Guillermo Garcia-Manero 1 , Hagop M Kantarjian 1 , Tapan M Kadia 1
Affiliation  

Venetoclax (VEN) in combination with a hypomethylating agent (HMA) has become the standard of care for patients aged >75 years and for those not eligible for intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The benefit of VEN-based therapy in patients who have newly diagnosed AML with mutations in the TP53 gene (TP53mut) over standard therapy is undefined.

中文翻译:

新诊断的 TP53 突变急性髓细胞白血病患者的结果,无论是否接受基于 venetoclax 的治疗

Venetoclax (VEN) 与低甲基化剂 (HMA) 联用已成为 75 岁以上患者和新诊断为急性髓性白血病 (AML) 且不适合接受强化化疗的患者的护理标准。对于新诊断为TP53基因 ( TP53 mut )突变的 AML 患者,基于 VEN 的治疗相对于标准治疗的益处尚未确定。
更新日期:2021-09-03
down
wechat
bug